Roshan Abraham

US-based Brighton Park Capital, a growth equity investment firm that focuses on software, technology-enabled services and healthcare sectors, has fully exited an Indian company it backed alongside larger private equity peer Carlyle a little more than five years ago.

Brighton Park has sold its entire remaining stake in Mumbai-listed lifesciences company Indegene Ltd through open market transactions. The PE firm offloaded an 8.7% stake in Indegene last week, stock-exchange data show, pocketing about Rs 1,105.3 crore ($116 million at current exchange rates). This comes amid a recovery in the company’s share price after falling to a one-year low in early March when the stock market had fallen in the wake of the US-Iran war.

The liquidity move follows the PE firm’s sale of a portion of its stake during Indegene’s initial public offering in 2024, along with Carlyle, and a partial exit through open market transactions last year.

Brighton Park invested about Rs 540-545 crore in the healthcare technology services provider in 2021 as part of a larger round. At the time, Indegene secured $200 million (around Rs 1,500 crore then) from Carlyle and Brighton Park. Carlyle itself pitched in around Rs 920 crore.  

Carlyle sold a small chunk of its holding to Avendus Future Leaders Fund in 2023. It then sold some stake during Indegene’s IPO for Rs 488 crore and divested its entire remaining stake of 10.2% in June last year for about Rs 1,447 crore ($168.5 million), generating an internal rate of return of 30-32% in rupee terms.

As for Brighton Park, it owed a little more than 12% in Indegene before the company’s IPO. It mopped up Rs 182.4 crore as part of the offer for sale in the IPO and then sold a small portion of its stake sometime between April and June last year. The exact timing of this partial exit couldn’t be ascertained but the firm is likely to have pocketed about Rs 100-110 crore, according to VCCircle estimates based on the prevailing share prices.

The latest tranche of exit last week likely helped the PE firm to generate an IRR of around 19-20% and a multiple on invested capital (MOIC) of close to 2.6x in rupee terms, on a first-in, first-out basis, according to VCCircle estimates. Overall, the company likely realised an IRR of about 21% from its entire investment, the estimates show. 

In dollar terms, which is more relevant for Brighton Park, the firm is likely to have scored an IRR of around 14% in the latest tranche and around 15-16% overall due to the rupee’s depreciation, the estimates show.

This broadly matches the minimum 20% IRR that PE firms target in local currency terms and 15% in dollar terms. 

Indegene, founded in 1998 by five first-generation entrepreneurs, provides technology platforms and commercialization services to pharmaceutical, biotechnology, and medical device companies. It also counts Infosys co-founder NS Raghavan as an investor.

US-based Brighton Park Capital, a growth equity investment firm that focuses on software, technology-enabled services ......

How did Brighton Park Capital fare as it logs off from India healthcare firm?

Healthcare

Life sciences and healthcare services firm Indegene Ltd has struck another deal in a little more than a month to bolster its presence in Europe with the acquisition of an Austrian healthcare communications company.

The Mumbai-listed, private-equity-backed company said it has signed a deal to fully acquire Vienna-headquartered Cake Kommunikations Holding GmbH or Cake Group and its European subsidiaries for up to 8.5 million euro ($9.8 million or Rs 87.1 crore) in an all-cash transaction, as per a stock exchange disclosure. 

The deal is subject to regulatory clearance based on the Austrian Investment Control Act (InvKG) and is expected to be completed in January 2026.

This is the second buyout Indegene has made recently to expand its global presence. On October 1, the company had announced the acquisition of a Pennsylvania-based specialised marketing services agency named BioPharm. This was part of Indegene's strategy to strengthen its commercialization portfolio with ad-tech, which combines AI and digital advertising for pharma companies.

The latest transaction will enhance Indegene's European presence and expand its capabilities in healthcare communications, Indegene said in a filing.

Cake Group operates across Austria, Germany and Switzerland. The healthcare marketing and communications agency offers services such as brand strategy, creative campaign development, and digital marketing solutions.

Headquartered in Vienna, Austria, the company has about 25 employees across the DACH (Austria, Germany and Switzerland) region. As of the financial year ended December 2024, Cake Group's revenue rose by about 22% year-on-year to 3.78 million euro, compared to a 2.5% y-o-y decline in revenue to 3.1 million euro a year before.

Acquisition-fuelled growth

Backed by private equity firm Brighton Park Capital and two Indian family offices, Indegene is building its marketing or communications services portfolio in the healthcare domain and growing its global footprint. 

The company had previously acquired a few other overseas companies to ramp up its service offerings. Last year, it purchased medical writing consultancy firm Trilogy Writing & Consulting GmbH. In 2022, it bought US-based CultHealth. The year before, it purchased US-based Medical Marketing Economics LLC.

Founded in 1998 by first-generation entrepreneurs Manish Gupta, Sanjay Parikh, Rajesh Nair, Gaurav Kapoor and Anand Kiran, the Bengaluru-based company went public last year through an initial public offering (IPO) that included an offer for sale by PE firms Carlyle and Brighton Park Capital and Infosys co-founder Nadathur S Raghavan's family office.

Its current set of investors include Brighton Park, the Nadathur Family Office, Enam Family Office, and PremjiInvest. 

Life sciences and healthcare services firm Indegene Ltd has struck another deal in a little more than a month to bolster......

PE-backed Indegene to acquire Austrian healthcare marketing firm

Life sciences and healthcare services company Indegene Ltd, which counts private equity firm Brighton Park Capital and two Indian family offices as investors, has inked a deal to acquire a US marketing services company. 

Mumbai-listed Indegene said in a stock exchange filing on Wednesday that it has agreed to acquire Pennsylvania-based BioPharm Parent Holding Inc for about $106 million in cash from Omnicom Health Group. 

The takeover will strengthen Indegene’s commercialization portfolio with ad-tech, which combines AI and digital advertising for pharma companies, thereby bolstering its position in the omnichannel and media space, it said.

“BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships," said Manish Gupta, Chairman and CEO of Indegene.

The acquisition comes at a time when many pharma companies find it difficult to manage mature product portfolios and ramp up capabilities for new launches, given healthcare professionals favor limited engagement. Indegene said with the acquisition it can provide commercialization models which combine rich data assets that will drive "significantly higher media ROI (return on investment) and enable more effective agentic operations."

“Their [Indegene’s] life sciences-contextualized approach to AI will open up new possibilities, helping us deliver deeper value to clients," said Steve Carickhoff, President, BioPharm.

BioPharm was founded in 2005. The marketing agency provides omnichannel strategy, end-to-end media journey which spans across strategy, planning and operations, and data-driven campaign execution. Its clients include 17 of the 25 major global biopharma companies.

For the financial year ended December 2024, the company recorded a revenue growth of 6% to $38.13 million, as against a 12% decline to $35.97 million in 2023. 

Indegene has acquired a few other overseas companies previously to ramp up its service offerings. Last year, it purchased medical writing consultancy firm Trilogy Writing & Consulting GmbH. In 2022, it bought US-based CultHealth. The year before, it purchased US-based Medical Marketing Economics LLC. 

Bengaluru-based Indegene was founded in 1998 by first-generation entrepreneurs Manish Gupta, Sanjay Parikh, Rajesh Nair, Gaurav Kapoor and Anand Kiran. The company went public last year through an IPO that included an offer for sale by PE firms Carlyle and Brighton Park Capital and Infosys co-founder Nadathur S Raghavan's family office.

Carlyle and Brighton Park had acquired a minority stake in the company for $200 million in 2021. Carlyle fully exited the company earlier this year. Its current investors include Brighton Park, the Nadathur Family Office, Enam Family Office, and PremjiInvest, the family office of Wipro’s Azim Premji which acquired a stake earlier this year.

Life sciences and healthcare services company Indegene Ltd, which counts private equity firm Brighton Park Capital and ......

PE-backed Indegene to acquire US firm for $106 mn

TEAM VCC

Premji Invest, the family office of Wipro founder chairman Azim Premji and one of the most active private equity-style investors in India, has expanded its portfolio with the addition of a newly listed company.

Bengaluru-based Premji Invest, which was set up two decades ago and manages over $15 billion in assets, bought 48.37 million shares of Vedanta Iron & Steel Ltd for Rs 101.7 crore ($10.7 million) in an open market transaction.

The investment, made earlier this month, gives Premji Invest a stake of 1.23% in Vedanta Iron & Steel, back-of-the-envelope calculations show.

Premji Invest bought the shares at Rs 21.02 apiece. The shares have jumped almost 33% since then and closed at Rs 28.10 apiece on the BSE on Tuesday, giving the company a market value of Rs 10,988 crore, stock-exchange data show. 

Vedanta Iron & Steel is one of India’s biggest iron ore producers and exporters with a capacity of 15 million tonnes per annum. It also operates steel plants with a capacity of 3 million tonnes a year. The company listed on stock exchanges earlier this month after demerging from Vedanta Ltd. It is one of four companies that spun out of Vedanta–the others are Vedanta Aluminium Metal Ltd, Vedanta Oil & Gas Ltd, and Vedanta Power Ltd.

Premji Invest makes early- and growth-stage investments in startups and also picks up minority stakes in listed companies. The bet on the Vedanta group company adds to its dealmaking activities this year after a busy 2025.

Last year, it invested in solar cell and module maker Premier Energies Ltd and life sciences company Indegene Ltd. It teamed up with Manipal Group chairman Ranjan Pai’s family office Claypond Capital to invest in Akasa Air, joined the cap table of Ajax Engineering Ltd, and made a follow-on investment in contract lifecycle management startup SpotDraft. It also invested in National Highways Infra Trust and wealth management firm Dezerv late last year.

Earlier this year, the family office increased its exposure to Anzen India Energy Yield Plus Trust, an energy-focused infrastructure investment trust (InvIT), by investing Rs 211.88 crore. It also invested in Maharashtra-based hospital chain NewEra Hospitals, picked up a small stake in CleanMax Enviro Energy as part of the anchor allotment ahead of the company’s initial public offering, and invested Rs 300 crore in a subsidiary of Bharat Forge.

Premji Invest is one of India's most active private investment firms. It has made more than 160 investments since inception across technology, healthcare, financial services, and consumer sectors.

Premji Invest, the family office of Wipro founder chairman Azim Premji and one of the most active private equity-style ......

Premji Invest adds another company to portfolio

Manufacturing

Sreeja Biswas

Indegene, a technology-led healthcare solutions provider to biopharmaceutical, biotech and medical devices companies, has acquired another overseas company to ramp up its service offerings. 

The Indian company, which is backed by US-based private equity firm Carlyle, has purchased medical writing consultancy firm Trilogy Writing & Consulting GmbH. 

Indegene said in a statement Trilogy's acquisition will enable it to broaden its tech-enabled medical writing services. It will also leverage Trilogy’s capabilities to help life sciences companies improve productivity, lower costs and quicken the pace of regulatory approvals for their products.  

The company didn’t disclose any financial terms of the transaction. 

Indegene has previously, too, acquired overseas companies. In 2022, for instance, it bought US-based CultHealth. The year before, it purchased US-based Medical Marketing Economics LLC. 

“Our investments in content automation, especially leveraging Generative AI, will further improve outcomes for our clients in clinical and regulatory writing and even beyond,” said Manish Gupta, chief executive officer of Indegene. 

Trilogy, with its presence across Germany, the UK, and the US, brings expertise in clinical, regulatory, safety, and medical content development. It specializes in various therapeutic areas including oncology, immunology, and neurosciences.  

“The deal will enable us to accelerate our growth and allow us to expand our tech-enabled medical writing services for our life sciences clients,” said Lisa Chamberlain James, senior partner at Trilogy.  

Bengaluru-based Indegene was founded in 1998 by first-generation entrepreneurs Manish Gupta, Sanjay Parikh, Rajesh Nair, Gaurav Kapoor and Anand Kiran. It provides product commercialization, enterprise marketing, data analytics, medical transformation, and learning and development services. 

The company is planning to float an initial public offering and received regulatory approval last year. The IPO includes an offer for sale of 36.3 million shares by Carlyle and Brighton Park Capital along with the Nadathur Family Office.  

VCCircle earlier reported that Carlyle trimmed its stake in Indegene, selling a portion of its shares to Avendus Future Leaders Fund. Carlyle and Brighton Park Capital acquired a minority stake in the company for $200 million in 2021. Carlyle owns a 20.79% stake in the company and Brighton Park holds a 12.27% stake. 

Indegene, a technology-led healthcare solutions provider to biopharmaceutical, biotech and medical devices companies, ......

Carlyle-backed Indegene makes another overseas acquisition

Indegene Ltd, a technology-led healthcare solutions provider to biopharmaceutical, biotech and medical devices companies, made a strong stock market debut on Monday with its shares gaining 26.25% on the first day of trade. 

Shares of Indegene, backed by private equity firm Carlyle, listed on BSE Ltd at Rs 659.70 apiece, up 46% from its initial public offering price of Rs 452. The shares fell to a low of Rs 527.80 apiece before closing at Rs 570.65, stock-exchange data show. At the closing level, the company commands a market capitalisation of Rs 13,653.88 crore ($1.64 billion). 

The strong listing comes after Indegene’s IPO recorded subscription of 69.66 times the shares on offer. It received bids for more than 2 billion shares against the 28.8 million shares on offer.  

Institutional investors bid for 197.55 times the portion reserved for them while non-institutional investors placed bids for 54.67 times their quota. The retail investors’ portion was covered 7.61 times.    

Indegene’s Rs 1,841.76-crore public offering comprised a fresh issuance of shares worth Rs 760 crore and an offer for sale of 23.9 million shares worth Rs 1,081.76 crore. The company garnered Rs 549 crore from anchor investors such as Abu Dhabi Investment Authority and a bunch of mutual funds ahead of the IPO. 

Carlyle and Brighton Park Capital, a private investment firm that specializes in software, information services, technology-enabled services and healthcare sectors, sold part of their stake in the IPO, albeit after modifying their original plan. The two investment firms had jointly bet $200 million (around Rs 1,500 crore then) on Indegene in March 2021, via a secondary sale from existing shareholders and a primary investment into the company.  

Both had trimmed their stake a year ago by selling a small chunk of their holding to Avendus Future Leaders Fund.  

Bengaluru-based Indegene was founded in 1998 by first-generation entrepreneurs Manish Gupta, Sanjay Parikh, Rajesh Nair, Gaurav Kapoor and Anand Kiran. It provides product commercialization, enterprise marketing, data analytics, medical transformation, and learning and development services.  

Indegene Ltd, a technology-led healthcare solutions provider to biopharmaceutical, biotech and medical devices ......

Carlyle-backed Indegene clocks 26% gain on stock market debut

Malvika Maloo

Private equity and venture capital-backed firms Indegene, a pharma player and skincare brand Mamaearth’s parent Honasa Consumer have received approval from Securities and Exchange Board of India (Sebi) for their respective initial public offerings.

Both companies had filed preliminary papers with the market regulator in December 2022, with an aim to raise primary and secondary capital through their public offering.

The approval comes at a time when the domestic market has responded strongly to a few companies that went public in the last few months.  

 

Indegene

Bengaluru-based Indegene Ltd, which offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, is planning to raise around Rs 950 crore through a fresh issue. 

In its offer for sale proposed earlier, which involved a sale of 36.3 million shares, US private equity giants Carlyle and Brighton Park Capital along with the Nadathur Family Office, were planning to make a partial exit.

However, Carlyle trimmed its stake a few months back, selling part of its shares to Avendus Future Leaders Fund, as reported earlier.

Indegene was founded in 1998 by five, first-generation entrepreneurs Manish Gupta, Sanjay Parikh, Rajesh Nair, Gaurav Kapoor and Anand Kiran. 

Nadathur Group (through Nadathur Fareast Pte. Ltd. and Vida Trustees Private Limited) holds 27.93% in Indegene. 

In 2021, Carlyle and Brighton Park Capital acquired a minority stake in the company for $200 million. Carlyle owns a 20.79% stake in the company and Brighton Park holds 12.27% stake. Carlyle plans to sell 37% of its holding, while Brighton will sell about 31%. 

 

Honasa Consumer

The parent of direct-to-consumer brands Mamaearth and The Derma Co, Honasa Consumer Pvt. Ltd, was reported looking to raise around Rs 2,900 crore, when it filed its papers.  The company, however, had put the plans on hold because of weak market conditions, according to Reuters.

The IPO comprises a fresh issue of Rs 400 crore and an offer-for-sale (OFS) of up to 46.82 million equity shares, according to draft red herring prospectus (DRHP) filed with Sebi.

Investors including Belgium’s Sofina Ventures, Stellaris, Fireside Ventures, and Evolvence, were looking to partially exit through the IPO. The company is also backed by Sequoia, which did not disclose its plans to sell its stake in the DRHP.

Fireside currently holds about 10.4% stake in the firm, Sofina and Stellaris hold about 9.5% and Evolvence around 1.4%.

Co-founder Varun Alagh, who currently holds 34.3% stake in the company planned to dilute about 3% of his holding, while Ghazal Alagh, who holds about 3.2%, aimed to dilute about 1% of her stake.

Investors like Kunal Bahl, Snapdeal co-founder Rohit Bansal, Bollywood actor Shilpa Shetty Kundra, Sharrp Ventures’s Rishabh Mariwala were also looking to dilute their stakes through the IPO.

Private equity and venture capital-backed firms Indegene, a pharma player and skincare brand Mamaearth’s parent Honasa......

Indegene, Mamaearth parent get SEBI approval for IPO

Finance

Siddhant Mishra

Three companies that are backed by private equity investors hit the market this week, with two launching their bids on Wednesday and one seeing a spectacular response from investors on the final day. 

Indegene Ltd, backed by Carlyle and Nadathur Holdings, recorded subscription of 69.66 times the shares on offer. It received bids for more than 2 billion shares against the 28.8 million shares on offer. Nadathur is the family office of Infosys co-founder Nadathur S Raghavan. It holds a 23.6% stake in Indegene while Carlyle holds 20.4%. 

Institutional investors bid for 197.55 times the portion reserved for them while non-institutional investors placed bids for 54.67 times their quota. The retail investors’ portion was covered 7.61 times.   

Indegene’s Rs 1,841.76-crore public offering comprises a fresh issuance of shares worth Rs 760 crore and an offer for sale of 23.9 million shares worth Rs 1,081.76 crore at the upper price band of Rs 452.   

Indegene, which provides digital services for the life sciences industry, garnered Rs 549 crore from anchor investors such as Abu Dhabi Investment Authority and a bunch of mutual funds ahead of the IPO. 

Aadhar Housing 

Blackstone-backed Aadhar Housing Finance’s Rs 3,000-crore IPO saw a lukewarm response on the first day, with total subscription of 43% of the issue size.    

The institutional investors’ segment was covered only 33% while non-institutional investors bid for 60% of the portion set aside for them. Retail investors subscribed for 41% of their quota.     

The IPO comprises a Rs 1,000-crore fresh share issuance and a Rs 2,000-crore offer for sale by the PE firm.  

Aadhaar Housing plans to use the capital to fulfill its capital requirements, besides general corporate purposes.   

In the run-up to the IPO, the company raised Rs 897.9 crore from anchor investors. Morgan Stanley, WF Asian Reconnaissance Fund, Clarus Capital, CLSA Global, and East Bridge Capital were among those who participated.   

Blackstone owns more than 98% of Aadhaar Housing Finance.    

TBO Tek 

Another company that launched its IPO on Wednesday was TBO Tek Ltd. Its IPO was fully subscribed. 

It saw an overall subscription of 1.17 times, with the retail category seeing a subscription of 3.23 times and non-institutional investor category being covered 2.09 times. However, institutional investors largely stayed away. 

The company is backed by PE firms General Atlantic and Affirma Capital. 

The IPO comprises a fresh issue of shares to raise Rs 400 crore and an offer of sale of 12.51 million shares by its promoters as well as Affirma. The PE firm is selling about 7.3 million shares, after it tweaked its exit plan. It currently holds 31.9 million shares, or a 30.59% stake, in TBO Tek. 

Three companies that are backed by private equity investors hit the market this week, with two launching their bids on ......

Carlyle-backed Indegene’s IPO gets bumper response; Aadhar Housing, TBO Tek make slow start

Ranjani Raghavan

Private equity firm Carlyle has trimmed its stake in Indegene, just two years after teaming up with another investment firm to joint betting $200 million (Rs 1,500 crore then) on the healthtech venture. 

Carlyle had joined hands with Brighton Park Capital, a private investment firm that focuses on software, information services, technology-enabled services and healthcare sectors, to invest in Indegene. The PE firm has offloaded some of its stake in IPO-bound Indigene to Avendus Future Leaders Fund. 

The Avendus fund picked up a stake in Indegene in a secondary transaction that values the healthtech company at over $1.5 billion, two people in the know said. Carlyle and another investor, whose name could not be ascertained, sold their shares to Avendus. 

Indegene declined to comment on the development. Carlyle did not respond to requests for comment. 

An Avendus spokesperson confirmed the news, saying the deal size was for $6.5 million (Rs 53.5 crore). Typically, the fund invests Rs 150-200 crore, he said. 

“It blended with the thesis of investing in established market leaders,” Ritesh Chandra, managing partner, Avendus Future Leaders Fund, said. 

The second series of Avendus Future Leaders Fund has a corpus of Rs 1,500 crore and has so far made six investments. These are Zeta, SBI General Insurance, Lenskart, Xpressbees, Licious and Juspay, apart from Indegene. 

The first fund of the series was launched in 2019 to raise $50 million. It invested in Lenskart, Delhivery, VerSe Innovation, Bikaji Foods, National Stock Exchange and Ujjivan Small Finance Bank, according to its website. 

Indegene had raised $200 million from Brighton Park Capital and Carlyle in February 2021. It had filed for an initial public offering to raise Rs 3,200 crore in December 2022. 

While the company plans to raise around Rs 950 crore in a primary fund infusion, there is also an offer for sale where existing investors will sell around 3.36 crore shares, according to its draft prospectus. 

Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle. 

Indegene’s revenue from operations came in at Rs 1,665 crore in FY22. It recorded a profit after tax of around Rs 163 crore. 

Private equity firm Carlyle has trimmed its stake in Indegene, just two years after teaming up with another investment ......

Carlyle makes a partial exit from IPO-bound Indegene

carlyle

Staff Writer

US private equity giant Carlyle and two other investors are planning to make partial exits from Indegene Ltd through an initial share sale of the technology-led healthcare solutions provider worth up to ₹3,200 crore.

Carlyle along with Brighton Park Capital and the Nadathur Family Office are proposing to sell less than half of their current holdings through the share sale, showed the draft prospectus filed by Indegene with the Securities and Exchange Board of India (Sebi) on Thursday.

The share sale will comprise a fresh issue of up to ₹950 crore and an offer for sale (OFS) of up to 36.3 million equity shares by existing shareholders that include a few promoters. The timeline for the share sale will be decided after regulatory approval.

Mint first reported about Indegene’s plans in September.

The funds raised through the share sale will be used to repay loans, meet capital expenditure, pay deferred amount for an earlier acquisition, fund inorganic growth and for general corporate purposes, the company said.

Nadathur Group (through Nadathur Fareast Pte. Ltd. and Vida Trustees Private Limited) holds 27.93% in Indegene.

In 2021, Carlyle and Brighton Park Capital acquired a minority stake in the company for $200 million (₹1,461 crore). Carlyle owns a 20.79% stake in the company and Brighton Park holds 12.27% stake. Carlyle plans to sell 37% of its holding, while Brighton will sell about 31%.

Kotak Mahindra Capital, Citigroup Global Markets India, JP Morgan India, Nomura Financial Advisory and Securities (India) are the book running lead managers to the issue.

Indegene was founded in 1998 by five, first-generation entrepreneurs Manish Gupta, Dr. Sanjay Parikh, Dr. Rajesh Nair, Gaurav Kapoor and Anand Kiran.

The Bengaluru-based firm is engaged in research and experimental development in natural sciences and engineering. It provides solutions such as product commercialization, enterprise marketing and customer experience, data and analytics, medical transformation and learning and development solutions. It mainly caters to bio-tech firms, medical device makers, and has a presence in the US, UK, Europe, China, Japan and India.

The company reported a net profit of ₹ 163 crore on revenue of ₹1,665 crore in the financial year ended 31 March 2022.

As of June-end, Indegene had 52 active clients. Its clients include 19 of the 20 largest, global biopharmaceutical companies. Indegene derives 66% of its revenue from North America, 27% from Europe, and 7% from other markets.

It catered to the domestic market until 2004 and later diversified into the overseas market. A little later, Infosys co-founder N.S. Raghavan’s Nadathur Holdings invested in the firm, offering an exit to KITVEN Fund, which had invested in 2002.

The company has been driving delivery excellence from six operational hubs and 16 offices located across North America, Europe and Asia. In the quarter ended June 2022, Indegene reported a net profit of ₹86 crore on revenue of ₹521 crore.

Industrialist and Infosys co-founder NS Raghavan and private equity firm Carlyle-backed Indegene Ltd has filed ......

Carlyle, two others to pare stakes in Indegene via IPO route

VC_Desk_Section_Masthead

VC_Desk_Section_A_300x250

VC_Desk_Section_B_300x250

VC_Desk_Section_C_300x250

VC_Desk_Section_D_300x250

VC_Desk_Section_E_300x250

VC_Desk_Section_A_Skyscraper

VC_Desk_Section_B_Skyscraper

VC_Desk_Section_A_Billboard

VC_Desk_Section_B_Billboard

VC_Desk_Section_C_Billboard

VC_Desk_Section_D_Billboard

VC_Desk_Section_E_Billboard

VC_Desk_Section_Footer

Asha Menon

India’s alternative investment fund industry is working out an informal arrangement to help each other transition into......

PE, VC industry making informal network to help angel funds meet accreditation deadline

Swet Sarika

Singapore-based healthcare-focussed Quadria Capital hit the final close of its third fund last year with $1.07 billion ......

Quadria's Sunil Thakur on speciality care, Gulf opportunity and more

Reuters

Markets

The Indian central bank's latest measures to support the plunging rupee will raise the cost of buying protection ......

RBI curbs to temper corporate rush to hedge against rupee weakness

Ajay Ramanathan

Vivifi India Finance Pvt Ltd, backed by investors including Viernes Holdco and BasePoint Capital, slipped into a net ......

Bottomline: Fintech lender Vivifi slips into loss as product pivot shrinks loan book

General

Private equity and venture capital investment activity improved this week, with both aggregate capital invested and deal......

Deals Digest: PE/VC funding value surges on Brookfield's bet

Airtel Money shares fell below their offer price on Friday, in a muted start to trading for the African mobile ......

How did Brighton Park Capital fare as it logs off from India healthcare firm?

PE-backed Indegene to acquire Austrian healthcare marketing firm

PE-backed Indegene to acquire US firm for $106 mn

Premji Invest adds another company to portfolio

Carlyle-backed Indegene makes another overseas acquisition

Carlyle-backed Indegene clocks 26% gain on stock market debut

Indegene, Mamaearth parent get SEBI approval for IPO

Carlyle-backed Indegene’s IPO gets bumper response; Aadhar Housing, TBO Tek make slow start

Carlyle makes a partial exit from IPO-bound Indegene

Carlyle, two others to pare stakes in Indegene via IPO route

Most Popular

Finance

PE, VC industry making informal network to help angel funds meet accreditation deadline

Finance

Quadria's Sunil Thakur on speciality care, Gulf opportunity and more

Markets

RBI curbs to temper corporate rush to hedge against rupee weakness

Finance

Bottomline: Fintech lender Vivifi slips into loss as product pivot shrinks loan book

General

Deals Digest: PE/VC funding value surges on Brookfield's bet

TMT

Airtel Money slips below IPO price in $7 bn London debut

Google News